Covid-19 - Pipeline Insight, 2025

DelveInsight’s, “Covid-19 - Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Covid-19 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Covid-19: Understanding

Covid-19: Overview

Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease causes respiratory illness (like the flu) with symptoms such as a cough, fever, and difficulty breathing. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Elderly people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. The COVID-19 virus is primarily transmitted through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. People can catch COVID-19 if they breathe in droplets from a person with COVID-19 who coughs out or exhales droplets. It also spreads when a person touches a surface or objects that has the virus on it, and then touches their eyes, nose, or mouth. The classification was initially based on antigenic relationships of the spike (S), membrane (M) and nucleocapsid (N) proteins and now re-enforced by viral genetic phylogeny.

Group 1: The HCoVs 229E and NL63

Group 2: OC43, HKU-1 and SARS coronaviruses

Group 3: avian infectious bronchitis virus, and other bird coronaviruses

In humans, there are four prototypic human CoV (hCoV) that cause endemic and epidemic respiratory disease, including the human alphacoronaviruses 229E and NL63 and the human betacoronaviruses OC43, HKU1, and SARS. Coronaviruses are a family of enveloped, single-stranded, positive-strand RNA viruses. The average diameter of the virus particles is around 120 nm (0.12 μm). The diameter of the envelope is ~80 nm (0.08 μm) and the spikes are ~20 nm (0.02 μm) long. The envelope of the virus in electron micrographs appears as a distinct pair of electron dense shells. Each SARS-CoV-2 virion is approximately 50–200 nm in diameter. Like other coronaviruses, SARS-CoV-2 has four structural proteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins; the N protein holds the RNA genome, and the S, E, and M proteins together create the viral envelope. The spike protein is the protein responsible for allowing the virus to attach to and fuse with the membrane of a host cell. Rapid and accurate detection of COVID-19 is crucial to control outbreaks in the community and in hospitals. Current diagnostic tests for coronavirus include reverse-transcription polymerase chain reaction (RT-PCR), real‐time RT-PCR (rRT‐PCR), and reverse transcription loop‐mediated isothermal amplification (RT‐LAMP). Due to the intense efforts of clinical researchers globally, significant progress has been made, which has led to a better understanding of not only COVID-19 and its management but also has resulted in the development of novel therapeutics and vaccine development at an unprecedented speed. Currently, a variety of therapeutic options are available that include antiviral drugs (e.g., molnupiravir, paxlovid, remdesivir), anti-SARS-CoV-2 monoclonal antibodies (e.g., bamlanivimab/etesevimab, casirivimab/imdevimab), anti-inflammatory drugs (e.g., dexamethasone), immunomodulators agents (e.g., baricitinib, tocilizumab) are available under FDA issued Emergency Use Authorization (EUA) or being evaluated in the management of COVID-19.

""Covid-19 - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Covid-19 pipeline landscape is provided which includes the disease overview and Covid-19 treatment guidelines. The assessment part of the report embraces, in depth Covid-19 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Covid-19 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Covid-19 R&D. The therapies under development are focused on novel approaches to treat/improve Covid-19.

Covid-19 Emerging Drugs Chapters

This segment of the Covid-19 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Covid-19 Emerging Drugs

• DAS181: Ansun Pharm

DAS181 is a recombinant sialidase enzyme that works by removing sialic acids from the lung surface so that influenza cannot bind to infect. This interrupts the virus lifecycle and allows patients the chance to recover. By targeting the host rather than the virus, DAS181 is less susceptible to drug resistant strains of virus, and by targeting the host rather than a specific virus, DAS181 works for other viruses that use sialic acid receptors. DAS181 is delivered in a nebulized formulation using Aerogen Solo aerosol drug delivery technology. The U.S. Food and Drug Administration (FDA) has granted both Fast Track and Breakthrough Therapy Designation to DAS181. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Covid-19.

• Sarconeos (BIO101): Biophytis

Sarconeos (BIO101) is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, it is believed that Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity in various age-related and muscular wasting conditions. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Covid-19.

• MP1032: MetrioPharm

MP1032 is a unique small molecule targeting overshooting reactions of activated immune cells by addressing a central, natural metabolic process occurring in activated immune cells. The mitochondria of these cells react to the activation by boosting their energy metabolism, which in turn leads to the generation of reactive oxygen species (ROS) and an increase of intercellular pH. MP1032 is activated only by clusters of elevated pH and acts as an ROS scavenger, normalizing the pathologically increased ROS levels (oxidative stress). Once the pH returns to normal, the drug stops is no longer activated and working. This unique, self-regulating mechanism of action makes MP1032 a first-in-class anti-inflammatory drug that reduces excessive ROS without interfering with the physiological ROS levels of other cells that are essential for normal cell function, resulting in an excellent safety profile. Currently, the drug is in Phase II stage of its development for the treatment of Covid-19.

• GLS-5310: GeneOne Life Science

GLS-5310 is a DNA vaccine encoding the spike (S) protein and a second antigenic target of SARS-CoV-2. StateGLS-5310 is being developed with support from the Government of Korea, through the Centers for Disease Control and Prevention, as part of a national project to develop COVID-19 vaccines. GLS-5310 is in pre-clinical development. Currently, the drug is in Phase I/II stage of its development for the treatment of Covid-19.

• S-892216: Shionogi

S-892216, developed by Sumitomo Pharma, is being investigated for its potential in treating COVID-19-related acute respiratory distress syndrome (ARDS). Acting as a serotonin 5-HT2A receptor agonist, it aims to regulate immune responses and mitigate excessive inflammation associated with severe COVID-19. The compound represents a novel approach to addressing cytokine storms and improving outcomes in critically ill patients. Currently the drug is in Phase I stage of its clinical development for the treatment of Covid-19.

Further product details are provided in the report……..

Covid-19: Therapeutic Assessment

This segment of the report provides insights about the different Covid-19 drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Covid-19
• There are approx. 180+ key companies which are developing the therapies for Covid-19. The companies which have their Covid-19 drug candidates in the most advanced stage, i.e. phase III include, Ansun Pharm
• Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Covid-19 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Covid-19: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Covid-19 therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Covid-19 drugs.

Covid-19 Report Insights

• Covid-19 Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Covid-19 Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Covid-19 drugs?
• How many Covid-19 drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Covid-19?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Covid-19 therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Covid-19 and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ansun Pharm
• Biophytis
• MetrioPharm
• GeneOne Life Science
• Shionogi
• Sinocelltech
• Laurent Pharmaceuticals
• Frontier Biotechnologies
• Eyegene
• aptaTargets
• Veru Inc.
• Corvus Pharmaceuticals
• Revive Therapeutics
• Regeneron Pharmaceuticals
• Hoffmann-La Roche
• CytoDyn
• Incyte Corporation/Novartis
• SAB Biotherapeutics
• Moderna Therapeutics
• Pfizer
• FibroGen
• Arch Biopartners
• Senhwa Biosciences
• Ionis Pharmaceuticals
• GlycoMimetics
• Akari Therapeutics
• Serpin Pharma

Key Products

• DAS181
• Sarconeos (BIO101)
• MP1032
• GLS-5310
• S-892216
• SCTV01E
• LAU-7b
• FB2001
• EG COVID vaccine
• ApTOLL
• VERU‑111
• Mupadolimab (CPI-006)
• Bucillamine
• REGN-COV2
• Tocilizumab
• Leronlimab
• Ruxolitinib
• SAB 185
• mRNA 1083
• Nirmatrelvir + ritonavir
• Pamrevlumab
• Metablok
• Silmitasertib
• Donidalorsen
• Uproleselan
• Nomacopan
• SP 16

Please Note: It will take 4-5 business days to complete the report upon order confirmation. Show more